Slower labs are to be paid less for Covid-19 tests, but will the move actually speed things up?
The new regulatory scheme poses problems – but also opportunities, in the shape of possible alignment with the US.
The SITC breaks its own embargo, and the ensuing chaos sees Replimune, Iovance and Incyte move.
The first of several perioperative Opdivo trials is said to read out positively, reminding the markets of such settings’ importance.
October brings US approval decisions for Eysuvis and Brilinta, while a panel meeting sets up a discussion around Covid-19 vaccines.